Wei‐Juin Su

3.3k citations
96 papers · 2.4k indexed · h-index 25

Wei‐Juin Su

92 papers receiving 2.3k citations

Peers

Wei‐Juin Su
Comparison fields: 5 of 124
  • Pharmacology 648
  • Infectious Diseases 1.0k
  • Epidemiology 877
  • Oncology 444
  • Hepatology 115
Replace John Bernardo with:
John Bernardo United States
Mario Regazzi Italy
Christine E. Staatz Australia
Robert M. Jasmer United States
Marc Pfister Switzerland
Wing-Wai Yew China
Christiane Pauli‐Magnus Switzerland
Alaa Badawi Canada
B G Gazzard United Kingdom
Bharat Damle United States
Wei‐Juin Su relative to John Bernardo United States John Bernardo's profile →
Citations per field
00.5×3.1×
John Bernardo · 1×
Citations per year

Countries citing papers authored by Wei‐Juin Su

Since Specialization
Citations

This map shows the geographic impact of Wei‐Juin Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Juin Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Juin Su more than expected).

Fields of papers citing papers by Wei‐Juin Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei‐Juin Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Juin Su. The network helps show where Wei‐Juin Su may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Wei‐Juin Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wei‐Juin Su Line = papers co-authored together Wei‐Juin Su links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 20241
4 20205
5 201924
6 201912
7 201714
8 201637
9 201531
10 20153
11 201411
12 20141
13 201266
14 201132
15 201117
16 201149
17 200817
18 20086
19 200531
20
Radionuclide imaging of spinal osteomyelitis: prospective comparison of FDG-PET and Ga-SPECT
20022

About Wei‐Juin Su

Wei‐Juin Su is a scholar working on Infectious Diseases, Epidemiology and Surgery, having authored 96 papers that have together received 2.4k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (55 papers), Mycobacterium research and diagnosis (27 papers), Diagnosis and treatment of tuberculosis (18 papers), Infectious Diseases and Tuberculosis (17 papers), Pneumocystis jirovecii pneumonia detection and treatment (11 papers), Lung Cancer Treatments and Mutations (7 papers), Respiratory Support and Mechanisms (4 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers). The work is most often cited by research in Pharmacology (648 citations), Infectious Diseases (1.0k citations) and Epidemiology (877 citations). Wei‐Juin Su has collaborated with scholars based in Taiwan, United States and China. Frequent co-authors include Full‐Young Chang, Shou‐Dong Lee, Yi‐Shin Huang, Herng‐Der Chern, Jia‐Yih Feng, Sheng‐Wei Pan, Vincent Yi‐Fong Su, Chi‐Huei Chiang, Shi-Chuan Chang and Kun‐Ta Chou. Their work appears in journals such as Medicine, CHEST Journal, Lung Cancer, Clinical Infectious Diseases and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026